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ABSTRACT
Objective To compare the risk of acute myocardial
infarction, heart failure, and death in patients with type 2
diabetes treated with rosiglitazone and pioglitazone.
Design Retrospective cohort study.
Setting Ontario, Canada.
Participants Outpatients aged 66 years and older who
were started on rosiglitazone or pioglitazone between 1
April 2002 and 31 March 2008.
Main outcome measure Composite of death or hospital
admission for either acute myocardial infarction or heart
failure. In a secondary analysis, each outcome was also
examined individually.
Results 39736 patients who started on either
pioglitazone or rosiglitazone were identified. During the
six year study period, the composite outcome was
reachedin895(5.3%)ofpatientstakingpioglitazoneand
1563 (6.9%) of patients taking rosiglitazone. After
extensive adjustment for demographic and clinical
factorsanddrugdoses,pioglitazonetreatedpatientshad
a lower risk of developing the primary outcome than did
patients treated with rosiglitazone (adjusted hazard ratio
0.83, 95% confidence interval 0.76 to 0.90). Secondary
analyses revealed a lower risk of death (adjusted hazard
ratio 0.86, 0.75 to 0.98) and heart failure (0.77, 0.69 to
0.87)withpioglitazonebutnosignificantdifferenceinthe
risk of acute myocardial infarction (0.95, 0.81 to 1.11).
Oneadditionalcompositeoutcomewouldbepredictedto
occur annually for every 93 patients treated with
rosiglitazone rather than pioglitazone.
Conclusions Among older patients with diabetes,
pioglitazoneisassociatedwithasignificantlylowerriskof
heart failure and death than is rosiglitazone. Given that
rosiglitazone lacks a distinct clinical advantage over
pioglitazone, continued use of rosiglitazone may not be
justified.
INTRODUCTION
Diabetes affects approximately 200 million people
worldwide, including more than a quarter of those
aged 65 and above in developed countries.
1 Although
diet and exercise are first line treatments, many
patients need treatment with oral hypoglycaemic
drugs or insulin with the goal of improving glycaemic
control and preventing microvascular and macrovas-
cular complications. Drugs that act as insulin sensiti-
sers have particular appeal because most patients
with type 2 diabetes show some degree of insulin
resistance.
2
The thiazolidinediones rosiglitazone and pioglita-
zoneareinsulinsensitisingagentsthatimproveglycae-
mic control and a variety of other surrogate outcomes
inpatientswithtype2diabetes.However,weightgain,
fluid retention, and heart failure have been reported
with both drugs.
34 The mechanism is incompletely
understood, but these effects seem to result at least in
part from stimulation of peroxisome proliferator acti-
vated receptors (PPARs), the primary physiological
mechanism by which these drugs improve glycaemic
control.Inthenephron,activationofPPARγpromotes
expression of epithelial sodium channels, increasing
the absorption of salt and water.
56 Rosiglitazone and
pioglitazone have both been associated with heart fail-
ure in case reports, observational studies, and rando-
mised trials. Consequently, the overall cardiovascular
safety of these drugs has been questioned.
378
In addition to concerns about heart failure, a recent
meta-analysis of 42 randomised trials comparing rosi-
glitazone with placebo or active treatment found an
increased risk of acute myocardial infarction and a
trend towards increased mortality with the drug.
9
However, many of the trials included in the study
were unpublished, the number of outcomes was rela-
tively low, and a Bayesian analysis of the original data
found no significant increase in the risk of myocardial
infarction and cardiovascular death during treatment
with rosiglitazone.
10 A subsequent meta-analysis con-
cluded that, compared with either placebo or treat-
ment with other oral hypoglycaemic agents, use of
rosiglitazone was associated with an increased risk of
myocardial infarction and heart failure but not cardio-
vascular mortality.
11
Concernsaboutthesafetyofrosiglitazoneprompted
an unplanned interim analysis of the Rosiglitazone
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Glycaemia in Diabetes (RECORD) trial, which
showed an increased risk of heart failure with the
drug but no increase in the death from cardiac causes
or all cause mortality.
12 However, the design, results,
and interpretation of this trial have been heavily
criticised.
13
Thecardiovascularrisksofrosiglitazonethusremain
incompletely characterised, and whether the adverse
effects of thiazolidinediones are a “class effect” is also
unclear.Bothdrugsseemtobecapableofprecipitating
heartfailure,butlimitedevidenceindicatesthatpiogli-
tazone may be associated with a lower risk of cardiac
events. It has more favourable effects on serum lipids
than does rosiglitazone,
1415 and a large randomised
trial of patients with existing macrovascular disease
suggested that treatment with pioglitazone prevents
cardiovascular events.
16 A subsequent meta-analysis
reached similar conclusions, in contrast to the meta-
analyses involving rosiglitazone,
17 and another meta-
analysisindicatedthatpioglitazonemightcarryalower
risk of heartfailure than doesrosiglitazone but with no
difference in death from cardiovascular causes.
18 Sev-
eral observational studies have provided conflicting
conclusionsaboutthecardiovascularsafetyofthethia-
zolidinediones, and the Food and Drug Administra-
tion has issued boxed warnings for both drugs.
18-23
Given the high prevalence of cardiovascular disease
inpatientswithdiabetes,aswellastheuncertaintyasto
whether rosiglitazone and pioglitazone carry differen-
tial cardiovascular risks and the impracticability of a
head to head trial of the two drugs, we explored the
relative cardiovascular safety of rosiglitazone and pio-
glitazone in a population of approximately 1.6 million
older outpatients.
METHODS
Setting
We did a population based retrospective cohort study
of Ontario residents aged 66 years or above who
started treatment with either rosiglitazone or pioglita-
zone between 1 April 2002 and 31 March 2008. These
people have universal access to hospital care, physi-
cians’ services, and prescription drug coverage.
Data sources
We examined the computerised prescription records
of the Ontario Public Drug Benefit Program, which
contains comprehensive records of prescription drugs
dispensedtoOntarioresidents65yearsofageorolder.
Wedidnotstudypatientsduringtheirfirstyearofelig-
ibility for prescription drug coverage (age 65) to avoid
incomplete drug records. We identified hospital visits
from the national ambulatory care reporting system
database and the Canadian Institute for Health infor-
mation discharge abstract database, which contain
detailed diagnostic and procedural information on
hospitaladmissions.WeusedtheOntariohealthinsur-
ance plan database to identify claims for inpatient and
outpatient physician services and the Ontario diabetes
database to determine the duration of diabetes in each
patient.
24 Basic demographic information, including
date of death, came from the registered persons data-
base,whichcontainsauniqueentryforallOntarioresi-
dents ever issued a health card. These databases are
routinely linked for the purposes of studying drug
safety,
25-27 and we linked them in an anonymous fash-
ion by using encrypted 10 digit health card numbers.
Design and analysis
Wedefinedtheindexdateasthedatewheneitherrosi-
glitazone or pioglitazone was first prescribed. To
include only patients naive to thiazolidinediones, we
excluded people who had received a prescription for
either of these drugs in the year before the index date.
We also excluded patients who had received a pre-
scription for insulin during the same interval, because
theadditionofathiazolidinedionetoinsulintreatment
is generally contraindicated and because we anti-
cipated that patients started on a thiazolidinedione
while on insulin were likely to be systematically differ-
ent from patients not receiving insulin. We included
patients who switched between low and high doses of
the same drug, but we censored those who switched
from one thiazolidinedione to the other, as well as
those who stopped receiving prescriptions for rosigli-
tazoneorpioglitazone,definedbythedateoftheirfinal
prescription plus 1.5 times the prescription days’ sup-
ply to avoid excluding patients who died or were
admittedto hospital during treatment.Finally, we cen-
soredafterthreeyearsoftotalobservationorattheend
of the study period (31 March 2008), whichever
occurred first.
Theprimaryoutcomewasacompositeofdeathfrom
any cause or admission to hospital or visit to an emer-
gency department for either acute myocardial infarc-
tionorheartfailure.Secondaryanalysesexploredeach
of these outcomes individually. We identified the date
of death by using the registered persons database and
hospital admissions for acute myocardial infarction
andheartfailurebyusingICD-10(internationalclassi-
fication of disease and related health problems, 10th
revision) codes I20, I21, I22 (for acute myocardial
infarctions), and I50 (for heart failure). The date of
death or admission served as the outcome date in all
analyses. We considered only the first admission for a
study outcome in patients who had multiple admis-
sions during the study period.
We compared patients’ baseline characteristics
between treatment groups by using standardised dif-
ferences—the difference in means divided by a pooled
estimate of the standard deviation of the variable. In
contrast to significance testing, standardised differ-
ences are not influenced by sample size; values lower
than 0.10 suggest negligible differences in the mean
value of the characteristic between groups.
28 We did
time to event analyses for the primary outcome with
rosiglitazone as reference because its risks, although
incompletely understood, are better characterised
than those of pioglitazone. The analysis incorporated
a dose-response assessment by considering low dose
pioglitazone (15 mg), high dose pioglitazone (30 mg
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and high dose rosiglitazone (8 mg) as time dependent
covariatesintheregressionmodel,withhighdoserosi-
glitazone as the reference group.
We constructed Kaplan-Meier curves to character-
isesurvivalovertimeamongpatientstreatedwithrosi-
glitazone or pioglitazone and made extensive
adjustments for demographic and clinical variables
(seewebappendix)byusingCoxproportionalhazards
regression. We verified the proportional hazards
assumptionby using visual inspection of the estimated
log(−log) survival curves and by testing the statistical
significance of a covariate that allowed treatment to
have a time varying effect.
Toestimatetheabsoluteriskofcardiovascularharm
for rosiglitazone relative to pioglitazone, we used the
fittedCoxproportionalhazardsmodeltoderiveamar-
ginalestimateofthenumberneededtotreattoharm.
29
From the fitted regression model, we calculated the
predicted probabilities of the primary outcome and
each secondary outcome at 365 days for each patient,
assuming treatment with rosiglitazone. We then deter-
mined the mean of these probabilities across the sam-
ple; this is the marginal (or population average)
probability of an event within 365 days, assuming
that all patients received rosiglitazone. We repeated
this exercise assuming that all patients received piogli-
tazone. We then calculated the difference between the
two marginal probabilities, assuming that all patients
were exposed to rosiglitazone and then that all were
exposed to pioglitazone. This is the marginal risk dif-
ference between rosiglitazone and pioglitazone at
365days,andtheinverseofthisrepresentsthenumber
needed to treat to harm. If no patients in the sample
experienced the event of interest on day 365, we used
linear interpolation to estimate the risk of the event on
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Fig 1 | Survival curves for primary outcome (composite of
death or hospital admission for acute myocardial infarction or
heart failure) from start of treatment with pioglitazone or
rosiglitazone, adjusted for factors outlined in web appendix
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Fig 2 | Survival curves for hospital admission for heart failure
from start of treatment with pioglitazone or rosiglitazone,
adjusted for factors outlined in web appendix
Table 1 |Characteristics of patients. Values are numbers (percentages) unless stated
otherwise
Variable
Pioglitazone
(n=16 951)
Rosiglitazone
(n=22 785)
Standardised
difference
Median (interquartile range) age (years) 72 (68-77) 72 (68-77) 0.01
Age group (years):
66-75 11 637 (68.7) 15 744 (69.1) 0.01
76-85 4 785 (28.2) 6 349 (27.9) 0.01
≥86 529 (3.1) 692 (3.0) 0.00
Male sex 8 839 (52.1) 12 094 (53.1) 0.02
Duration of diabetes (years):
<2 1 179 (7.0) 1 367 (6.0) 0.04
2-5 1 921 (11.3) 2 430 (10.7) 0.02
>5 13 851 (81.7) 18 988 (83.3) 0.04
Cardiovascular admissions and procedures in
previous 5 years:
Acute myocardial infarction 591 (3.5) 927 (4.1) 0.03
Congestive heart failure 260 (1.5) 401 (1.8) 0.02
Angina 962 (5.7) 1 426 (6.3) 0.02
Percutaneous coronary intervention 482 (2.8) 697 (3.1) 0.01
Coronary artery bypass grafting 447 (2.6) 684 (3.0) 0.02
Coronary angiography 1 478 (8.7) 2 168 (9.5) 0.03
Charlson score:
0 4 704 (27.8) 6 322 (27.7) 0.00
1 2 909 (17.2) 4 041 (17.7) 0.02
≥2 3 472 (20.5) 4 978 (21.8) 0.03
Not available 5 866 (34.6) 7 444 (32.7) 0.04
History of drug use in previous year:
Angiotensin converting enzyme inhibitors 10 252 (60.5) 14 414 (63.3) 0.06
Angiotensin receptor antagonists 5 248 (31.0) 6 260 (27.5) 0.08
Aspirin 2 993 (17.7) 3 846 (16.9) 0.02
Other antiplatelet drugs 793 (4.7) 1 108 (4.9) 0.01
β adrenergic antagonists 5 518 (32.6) 7 665 (33.6) 0.02
Calcium channel blockers 6 797 (40.1) 8 842 (38.8) 0.03
Nitrates 1 950 (11.5) 2 769 (12.2) 0.02
Thiazide diuretics 4 052 (23.9) 5 595 (24.6) 0.02
Other diuretics 3 156 (18.6) 4 461 (19.6) 0.02
Spironolactone 414 (2.4) 566 (2.5) 0.00
Statins 12 168 (71.8) 16 300 (71.5) 0.01
Digoxin 743 (4.4) 1 030 (4.5) 0.01
Non-steroidal anti-inflammatory drugs 6 996 (41.3) 9 178 (40.3) 0.02
Median (interquartile range) No of distinct drugs in
previous year
10 (7-13) 10 (7-13) 0.03
Other oral hypoglycaemic agents in previous year:
Metformin 13 677 (80.7) 18 496 (81.2) 0.01
Sulphonylureas 11 628 (68.6) 15 710 (68.9) 0.01
Acarbose 1 005 (5.9) 1 152 (5.1) 0.04
Meglitinides 159 (0.9) 176 (0.8) 0.02
History of renal disease in previous 5 years 575 (3.4) 867 (3.8) 0.02
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with one event time preceding and one event time fol-
lowing day 365.
RESULTS
During the 72 month study period, we identified
39736patientswhostartedtreatmentwithathiazolidi-
nedione,of whom 22785 (57.3%) started rosiglitazone
treatment and 16951 (42.7%) started on pioglitazone.
We followed patients on rosiglitazone for a median of
292 (interquartile range 124-448) days and those on
pioglitazoneforamedianof294(87-487)days.Collec-
tively,we followed patientsfora totalof38752 person
yearsoftreatment.Table 1showsthecharacteristicsof
the patients. Overall, patients starting treatment with
rosiglitazone and pioglitazone were highly similar in
termsofdemographics,medicalillnesses,comorbidity
measures, and concomitant drug use.
In total, 1563 (6.9%) patients receiving rosiglitazone
and 895 (5.3%) receiving pioglitazone reached the pri-
marycompositeoutcomeofdeathoradmissiontohos-
pital for either acute myocardial infarction or
congestive heart failure (fig 1). After extensive adjust-
ment for potential confounding factors, we found that
pioglitazone was associated with a significantly lower
risk of the primary outcome compared with rosiglita-
zone(adjustedhazardratio0.83,95%confidenceinter-
val 0.76 to 0.90). In terms of absolute risk, we estimate
thatapproximatelyoneadditionalcompositeoutcome
would be expected to occur annually for every 93
patients treated with rosiglitazone rather than pioglita-
zone.
Inthesecondaryanalysesofeachoutcomeindividu-
ally, we studied 1330 admissions for heart failure, 698
admissions for acute myocardial infarction, and 1022
deaths (table 2). We found a lower risk of congestive
heart failure during pioglitazone treatment compared
with rosiglitazone treatment (adjusted hazard ratio
0.77, 0.69 to 0.87) (fig 2) but no significant difference
in the risk of myocardial infarction (0.95, 0.81 to 1.11)
(fig 3). Notably, patients treated with pioglitazone had
a lower risk of death from all causes than did those
treated with rosiglitazone (adjusted hazard ratio 0.86,
0.75 to 0.98) (fig 4). The estimated annual number
needed to treat to harm for rosiglitazone compared
with pioglitazone was 120 for congestive heart failure
and 269 for death from any cause.
Totesttherobustnessofourconclusions,wedidsev-
eral additionalanalyses. Inthe dose-responseanalysis,
compared with high dose rosiglitazone, low dose rosi-
glitazone was not associated with a significantly lower
risk of the composite outcome (adjusted hazard ratio
0.94, 0.83 to 1.07), whereas both high dose pioglita-
zone (0.76, 0.66 to 0.88) and low dose pioglitazone
(0.83, 0.70 to 0.97) were. We replicated our analyses
after excluding patients with heart failure or acute
myocardial infarction who were assessed in the emer-
gency department but not subsequently admitted to
hospital. The findings were consistent with those
obtained by using the full cohort. We also found simi-
lar results when we replicated our analyses without
censoring after three years of treatment. Finally,
because the meta-analysis of Nissen and Wolski
received considerable media attention and influenced
thiazolidinedione prescribing trends,
30 we repeated
our analyses but terminated follow-up one year earlier
(31 March 2007) to reduce any potential contamina-
tion of our findings by changes in practice resulting
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Fig 3 | Survival curves for hospital admission for acute
myocardial infarction from start of treatment with
pioglitazone or rosiglitazone, adjusted for factors outlined in
web appendix
Table 2 |Risk of adverse cardiovascular events among patients treated with pioglitazone or
rosiglitazone
Events in
pioglitazone
patients
(n=16 951)
Events in
rosiglitazone
patients
(n=22 785)
Unadjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)*
Primary outcome 895 1563 0.81 (0.74 to 0.87) 0.83 (0.76 to 0.90)
Secondary outcomes:
Heart failure 461 869 0.75 (0.67 to 0.84) 0.77 (0.69 to 0.87)
Myocardial infarction 273 425 0.91 (0.78 to 1.06) 0.95 (0.81 to 1.11)
Death 377 645 0.82 (0.73 to 0.94) 0.86 (0.75 to 0.98)
*Cox proportional hazards model estimates adjusted for age; sex; duration of diabetes; residence in long term
care facility; socioeconomic status (estimated from median residential income fifth); year of cohort entry;
Charlson comorbidity index; number of distinct drugs in year before cohort entry; history in previous five years
of renal disease or hospital admission for acute myocardial infarction, angina, congestive heart failure, coronary
angiography, coronary artery bypass grafting, or percutaneous coronary intervention; and receipt in year
preceding cohort entry of angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, β
adrenergic antagonists, aspirin, other antiplatelet drugs, nitrates, calcium channel antagonists, thiazide
diuretics, spironolactone, other diuretics, hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins),
digoxin, non-steroidal anti-inflammatory drugs, metformin, sulphonylureas, acarbose, or meglitinides.
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Fig 4 | Survival curves for death from any cause from start of
treatment with pioglitazone or rosiglitazone, adjusted for
factors outlined in web appendix
RESEARCH
page 4 of 6 BMJ | ONLINE FIRST | bmj.comfrom publication of the meta-analysis. These findings
were again consistent with those derived by using the
original study interval.
DISCUSSION
Using the population based healthcare records of
approximately 40000 patients who started treatment
with a thiazolidinedione over a six year period, we
found considerable differences in the risk of heart fail-
ure and death between users of rosiglitazone and pio-
glitazone but no significant difference in the risk of
myocardial infarction. Our findings suggest clinically
important differences in the cardiovascular safety pro-
files of rosiglitazone and pioglitazone in clinical
practice.
Interpretation of findings
Adverse effects of a class of drugs (class effects) are
common in clinical medicine, and recent studies high-
lighting the cardiovascular risks of rosiglitazone have
naturally raised questions about the safety of pioglita-
zone. Consequently, patients and clinicians have been
faced with difficult decisions on the use of these drugs,
which are often prescribed to patients with type 2 dia-
beteswhoseresponsetootheroralagentsissuboptimal
but who are reluctant to start insulin. Our study pro-
videsdirectevidenceinotherwisecomparablepatients
that pioglitazone is associated with a lower risk of
adversecardiovasculareventsanddeaththanisrosigli-
tazone.
Whypioglitazonemightbesaferthanrosiglitazoneis
not fully understood,but the possibilityissupported by
converging lines of evidence. Pioglitazone has more
favourable effects on serum lipids than does
rosiglitazone,
1415 and some evidence suggests that it
also imparts anti-inflammatory and anti-atherogenic
effects.
31 Rosiglitazone is a far more potent agonist of
PPARγ than is pioglitazone,
32 and activation of PPARγ
in the kidney seems to be an important mechanism of
thiazolidinedione induced salt and water retention.
5
These observations may explain the higher risk of
heart failure with rosiglitazone, and we speculate that
they also underliethe increasedriskofdeathinpatients
taking the drug. Unlike rosiglitazone, pioglitazone has
been found to significantly reduce ischaemic cardio-
vascularoutcomesinalargerandomisedtrialandacor-
responding meta-analysis.
1617 Furthermore, although
observational studies have reached differing conclu-
sionsabout the relativesafetyofthe thiazolidinediones,
nostudieshavesuggestedasafetyadvantageforrosigli-
tazone.
Limitations
The main limitation of our study is the possibility that
patients who were prescribed rosiglitazone were at a
higher baseline risk of heart failure and death than
those prescribed pioglitazone. However, several
observations make this an unlikely explanation for
our findings. The two groups of patients were highly
similar (table 1), and any discrepancies are too minor
to be likely to explain the large effect sizes seen in our
study. Our findings are supported by biological
plausibility,
5 and the adjusted and unadjusted hazard
ratios were similar. Finally, if the increased risks of
heart failure and death with rosiglitazone simply
reflected increased cardiac risk at baseline, one would
expecttoseeasimilarincreaseintheriskofacutemyo-
cardial infarction. This was not the case.
Other limitations of our work merit emphasis. Our
findings derive from patients aged 66 years and older,
and the generalisability of our findings to younger
patients is not known. Miscoding is a potential threat
tothevalidityofallobservationalstudies,butprevious
validation studies estimate the positive predictive
value of heart failure and myocardial infarction in our
databases at approximately 90%.
3334 Moreover, differ-
ential miscoding between users of rosiglitazone and
pioglitazone would be implausible in this setting.
Our study was designed to explore the comparative
safety of pioglitazone and rosiglitazone. We cannot
provide an assessment of the safety of pioglitazone
relative to other hypoglycaemic agents, and our find-
ings should not be interpreted as evidence that piogli-
tazone is devoid of cardiovascular toxicity. As with
rosiglitazone, good evidence exists to show that the
drug can cause heart failure.
161735 Unlike for rosiglita-
zone, however, no evidence exists to show that piogli-
tazone increases ischaemic events, and some evidence
indicates that it may reduce cardiovascular morbidity
inhighriskpatientswithdiabetes.
1617Furtherresearch
isneededtofullycharacterisethesafetyprofileandnet
benefits of pioglitazone in clinical practice.
Conclusions and policy implications
In a large cohort of older patients starting treatment
with a thiazolidinedione, we found that pioglitazone
was associated with a lower risk of adverse cardio-
vascular events and death than was rosiglitazone.
Giventhe accumulatingevidence ofharmwithrosigli-
tazone treatment and the lack of a distinct clinical
advantage for the drug over pioglitazone, questioning
whether ongoing use of rosiglitazone is justified in any
circumstance is reasonable. Pending the availability of
additional data on the benefits and harms of these
drugs and a clarification of their role in the
WHAT IS ALREADY KNOWN ON THIS TOPIC
Rosiglitazone and pioglitazone have been associated with congestive heart failure, and
rosiglitazone has also been associated with acute myocardial infarction
Whether clinically important differences exist in the cardiac safety profiles of these drugs
remains unclear
WHAT THIS STUDY ADDS
Rosiglitazone is associated with a clinically significant higher risk of heart failure and death
than is pioglitazone but with no major difference in the risk of acute myocardial infarction
Given the absence of a distinct clinical advantage over pioglitazone, continued use of
rosiglitazone is difficult to advocate
The long term safety of pioglitazone compared with other oral hypoglycaemic drugs remains
uncertain
RESEARCH
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clinicians should re-evaluate the appropriateness of
new or ongoing treatment with rosiglitazone.
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